Drugs / NORARAMTIDE
NORARAMTIDE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04634435 | Oct 2021 → Jan 2025 | plasma cell myeloma | Biohaven Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NORARAMTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068397 ↗ |
| Known as | BHV-1100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04634435 ↗ |
| Known as | KP-1237 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068397 ↗ |
| Known as | Noraramtida | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068397 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068397 ↗ |